<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="case-report" dtd-version="1.0" xml:lang="ko" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">KJORL</journal-id>
<journal-title-group>
<journal-title>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</journal-title><abbrev-journal-title>Korean J Otorhinolaryngol-Head Neck Surg</abbrev-journal-title></journal-title-group>
<issn pub-type="ppub">2092-5859</issn>
<issn pub-type="epub">2092-6529</issn>
<publisher>
<publisher-name>Korean Society of Otolaryngology-Head and Neck Surgery</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3342/kjorl-hns.2021.00269</article-id>
<article-id pub-id-type="publisher-id">kjorl-hns-2021-00269</article-id>
<article-categories>
<subj-group>
<subject>Case Report</subject></subj-group></article-categories>
<title-group>
<article-title>가성대에 발생한 상피 모양 변이 고등급 점액 섬유육종 1예</article-title>
<trans-title-group>
<trans-title xml:lang="en">Epithelioid Variant of High-Grade Myxofibrosarcoma in the False Vocal Fold: A Case Report</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5791-2607</contrib-id>
<name-alternatives>
<name name-style="western" xml:lang="en"><surname>Song</surname><given-names>Seulki</given-names></name>
<name name-style="eastern" xml:lang="ko"><surname>송</surname><given-names>슬기</given-names></name>
</name-alternatives>
<xref ref-type="aff" rid="af1-kjorl-hns-2021-00269"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name-alternatives>
<name name-style="western" xml:lang="en"><surname>Song</surname><given-names>Dae Hyun</given-names></name>
<name name-style="eastern" xml:lang="ko"><surname>송</surname><given-names>대현</given-names></name>
</name-alternatives>
<xref ref-type="aff" rid="af2-kjorl-hns-2021-00269"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6137-8232</contrib-id>
<name-alternatives>
<name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>Jin Pyeong</given-names></name>
<name name-style="eastern" xml:lang="ko"><surname>김</surname><given-names>진평</given-names></name>
</name-alternatives>
<xref ref-type="corresp" rid="c1-kjorl-hns-2021-00269"/>
<xref ref-type="aff" rid="af1-kjorl-hns-2021-00269"><sup>1</sup></xref>
</contrib>
<aff-alternatives id="af1-kjorl-hns-2021-00269">
<aff xml:lang="en"><label>1</label>Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon, <country>Korea</country></aff>
<aff xml:lang="ko"><label>1</label>경상국립대학교 의과대학 이비인후과학교실, 창원경상국립대학교병원</aff>
</aff-alternatives>
<aff-alternatives id="af2-kjorl-hns-2021-00269">
<aff xml:lang="en"><label>2</label>Department of Pathology, Gyeongsang National University College of Medicine, Institute of Health Science, Gyeongsang National University Changwon Hospital, Changwon, <country>Korea</country></aff>
<aff xml:lang="ko"><label>2</label>경상국립대학교 의과대학 병리학교실, 경상국립대학교 건강과학연구원</aff>
</aff-alternatives>
</contrib-group>
<author-notes>
<corresp id="c1-kjorl-hns-2021-00269">Address for correspondence Jin Pyeong Kim, MD, PhD Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11 Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea Tel +82-55-214-2799 Fax +82-55-214-1410 E-mail <email>jinpyeong@gnu.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>12</month>
<year>2021</year></pub-date>
<volume>64</volume>
<issue>12</issue>
<fpage>954</fpage>
<lpage>958</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>4</month>
<year>2021</year></date>
<date date-type="rev-recd">
<day>20</day>
<month>6</month>
<year>2021</year></date>
<date date-type="accepted">
<day>28</day>
<month>6</month>
<year>2021</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000a9; 2021 Korean Society of Otorhinolaryngology-Head and Neck Surgery</copyright-statement>
<copyright-year>2021</copyright-year>
<license>
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<trans-abstract xml:lang="en"><p>Myxofibrosarcoma (MFS) is a histologic subtype of malignant fibrous histiocytoma (MFH), with a predominant myxoid component. MFS is characterized by locally aggressive behavior and a high rate of local recurrence, however, with a good prognosis. Head and neck MFS accounts for 3% of all cases of MFS. To date, only two cases of laryngeal MFS have been reported. Owing to the rarity of MFS, the clinical characteristics and optimal treatment options remain controversial. Surgical resection with a clear margin is considered the treatment of choice. Compared to traditional MFS tumors, epithelioid variants have worse prognosis. Other factors associated with a poor prognosis of MFS tumors include inadequate surgical margins, large tumor size, old age, and high-grade tumors. Herein, we report a case of high-grade epithelioid variant MFS located in the false vocal fold, requiring total laryngectomy to obtain an adequate surgical margin. To our knowledge, this is the first case report of epithelioid variant of high-grade MFS presenting in the larynx.</p></trans-abstract>
<kwd-group xml:lang="en">
<kwd>Fibrosarcoma</kwd>
<kwd>Larynx</kwd>
<kwd>Malignant fibrous histiocytoma</kwd>
<kwd>Sarcoma</kwd>
<kwd>Soft tissue neopla</kwd>
</kwd-group>
</article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Sarcomas account for less than 1% of head and neck malignancies &#x0005b;<xref ref-type="bibr" rid="b1-kjorl-hns-2021-00269">1</xref>&#x0005d;. Head and neck sarcomas represent only 5%-15% of all sarcomas in adults &#x0005b;<xref ref-type="bibr" rid="b2-kjorl-hns-2021-00269">2</xref>&#x0005d;. The most common histologic types of sarcomas in the head and neck region are rhabdomyosarcoma, osteosarcoma, malignant fibrous histiocytoma (MFH), and angiosarcoma.</p>
<p>Myxofibrosarcoma (MFS) is a histologic subtype of MFH that has been previously confused with multiple entities of MFH. The rapid development of immunohistochemical and genetic/molecular studies have established a distinct diagnosis of MFS &#x0005b;<xref ref-type="bibr" rid="b3-kjorl-hns-2021-00269">3</xref>&#x0005d;. However, due to the rarity of MFS, the clinical behavior and outcome of MFS tumors are uncertain; moreover, there are no randomized clinical trials to establish treatment guidelines &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d;.</p>
<p>Herein, we report a case of MFS on a false vocal fold, with the patient presenting with voice changes and progressive dyspnea. To our knowledge, this is the first case of high-grade MFS in the larynx with an epithelioid variant.</p>
</sec>
<sec sec-type="cases">
<title>Case</title>
<p>A 79-year-old male presented to our outpatient clinic with complaints of change in his voice that began one month prior. The patient had no history of smoking or prior irradiation. He suffered from hypertension, diabetes, and cerebrovascular disease with severe stenosis. Laryngoscopic examination revealed a mass-like lesion on the left false vocal fold (<xref rid="f1-kjorl-hns-2021-00269" ref-type="fig">Fig. 1A</xref>), with intact vocal fold mobility. There were no abnormal findings on esophagogastroduodenoscopy. Initial CT and MRI of the neck revealed a heterogeneously enhancing mass in the left false vocal fold and aryepiglottic fold, with invasion of the paraglottic fat (<xref rid="f1-kjorl-hns-2021-00269" ref-type="fig">Fig. 1B</xref> and <xref rid="f1-kjorl-hns-2021-00269" ref-type="fig">C</xref>). However, no definite metastatic lymph node was identified in the neck, bilaterally. Rigid laryngoscopy and punch biopsy of the left false vocal fold mass were performed under general anesthesia. Punch biopsy revealed a spindle cell sarcoma with a myxoid component, suggestive of MFS. There was no distant lesion on positron emission tomography. Even with enough consultation, the patient wanted radiotherapy as a primary treatment. Soon after referring to radiation oncologist, the patient visited the emergency room for dyspnea 5 days after rigid endoscopy and underwent emergent tracheostomy. As the tumor was large and aggressively growing, with involvement of the paraglottic space, and considering patient&#x02019;s characteristics (old age, poor pulmonary function, and multiple co-morbidities), total laryngectomy was performed 1 week after the tracheostomy. Final histopathology confirmed a high-grade MFS, with a maximum tumor diameter of 3 cm. The tumor was composed of spindle cells with a myxoid background (<xref rid="f2-kjorl-hns-2021-00269" ref-type="fig">Fig. 2A</xref> and <xref rid="f2-kjorl-hns-2021-00269" ref-type="fig">B</xref>), which did not react with cytokeratin antibody (<xref rid="f2-kjorl-hns-2021-00269" ref-type="fig">Fig. 2C</xref>). Immunohistochemical staining using vimentin and CD31 was positive (<xref rid="f2-kjorl-hns-2021-00269" ref-type="fig">Fig. 2D</xref> and <xref rid="f2-kjorl-hns-2021-00269" ref-type="fig">E</xref>). Partial epithelioid features were identified with vascular invasion (<xref rid="f3-kjorl-hns-2021-00269" ref-type="fig">Fig. 3</xref>). The aforementioned pathologic results were consistent with a high-grade epithelioid variant MFS. The patient was discharged 14 days after surgery without complications and was followed up for 4 months with no tumor recurrence.</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>MFS was firstly described as a &#x0201c;myxoid variant of MFH&#x0201d; by Weiss and Enzinger &#x0005b;<xref ref-type="bibr" rid="b5-kjorl-hns-2021-00269">5</xref>&#x0005d; in 1977. They reported that the myxoid variant of MFH exhibited a better prognosis than other forms of MFH tumors &#x0005b;<xref ref-type="bibr" rid="b5-kjorl-hns-2021-00269">5</xref>&#x0005d;. Owing to various efforts to distinguish MFS from a variety of histological types of MFH, as well as advances in immunohistochemistry and molecular techniques, the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone recommended the use of the term MFS instead of myxoid variant MFH&#x0005b;<xref ref-type="bibr" rid="b3-kjorl-hns-2021-00269">3</xref>&#x0005d;. Patients presenting with MFS are generally 50 to 70 years of age and are more commonly men &#x0005b;<xref ref-type="bibr" rid="b6-kjorl-hns-2021-00269">6</xref>&#x0005d;. The most common site of involvement is the extremities (77%), with an incidence rate of 3% in the head and neck region &#x0005b;<xref ref-type="bibr" rid="b6-kjorl-hns-2021-00269">6</xref>-<xref ref-type="bibr" rid="b8-kjorl-hns-2021-00269">8</xref>&#x0005d;. Owing to the multidirectional spread of MFS along the facial planes and its infiltrative growth pattern, obtaining a clear surgical margin may be challenging &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d;. For this reason, MRI is the diagnostic modality of choice to identify the extent of the tumor preoperatively &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d;. Surgical resection is the treatment of choice for patients presenting with MFS. There is no randomized controlled study specific to MFS evaluating the treatment outcome of surgery compared to radiotherapy. The national comprehensive cancer network (NCCN) clinical practice guideline in soft tissue sarcoma recommends surgical wide excision as a primary treatment option when soft tissue sarcoma in head and neck is resectable&#x0005b;<xref ref-type="bibr" rid="b8-kjorl-hns-2021-00269">8</xref>&#x0005d;. And one retrospective study reported the patients treated with radiotherapy had the same prognosis as untreated patients. Although radiotherapy as a definitive treatment in MFS seems to have poor oncologic outcome, the neo-adjuvant or adjuvant therapies with surgery have a benefit of reducing potential local and distant recurrences &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d;.</p>
<p>MFS has a relatively better prognosis than the other histological subtypes of sarcomas, such as leiomyosarcoma, with the 5-year overall survival ranging from 61% to 82.6% &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>,<xref ref-type="bibr" rid="b9-kjorl-hns-2021-00269">9</xref>&#x0005d;. However, MFS is a locally aggressive tumor with a high rate of local recurrence of 16%-57% and with a median time to recurrence of 8.2-27 months &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>,<xref ref-type="bibr" rid="b9-kjorl-hns-2021-00269">9</xref>,<xref ref-type="bibr" rid="b10-kjorl-hns-2021-00269">10</xref>&#x0005d;. For this reason, wide resection, including a 2 cm free margin from the tumor, is recommended. Prognostic factors have been investigated, with inadequate surgical resection margins, large tumor size, old age, and high-grade histology found to be significant poor prognostic factors for overall survival &#x0005b;<xref ref-type="bibr" rid="b9-kjorl-hns-2021-00269">9</xref>,<xref ref-type="bibr" rid="b10-kjorl-hns-2021-00269">10</xref>&#x0005d;.</p>
<p>Various grading systems have been developed for MFS, with the French Federation of Cancer Centers Sarcoma Group system and the National Cancer Institute system being the most widely recognized. These systems include three groups of soft tissue sarcomas, as low-, intermediate-, and high-grade &#x0005b;<xref ref-type="bibr" rid="b11-kjorl-hns-2021-00269">11</xref>,<xref ref-type="bibr" rid="b12-kjorl-hns-2021-00269">12</xref>&#x0005d;. The recurrence rate of high-grade tumors is 62%, which is higher than the rate for low-grade tumors (48%) &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d;. Rarely, epithelioid cells, rather than spindle cells, can be observed within the myxoid area of the MFS, with the epithelioid variant of MFS having a poor prognosis compared to traditional spindle cell MFS. Nascimento, et al. &#x0005b;<xref ref-type="bibr" rid="b13-kjorl-hns-2021-00269">13</xref>&#x0005d; reported the epithelioid variant to be more aggressive than the traditional spindle cell MFS, with a rate of local recurrence of 70% and a rate of metastases of 50%. Scoccianti, et al. &#x0005b;<xref ref-type="bibr" rid="b9-kjorl-hns-2021-00269">9</xref>&#x0005d; reported the presence of an epithelioid variant pattern as a negative prognostic factor for disease-specific survival, local recurrence free survival, and metastases free survival. In fact, the reported rate of disease-specific survival of 53.6% for the epithelioid subtype of MFS is markedly lower than the survival rate for low-grade (100%) and high-grade (77.7%) tumors &#x0005b;<xref ref-type="bibr" rid="b9-kjorl-hns-2021-00269">9</xref>&#x0005d;.</p>
<p>Gugatschka, et al. &#x0005b;<xref ref-type="bibr" rid="b14-kjorl-hns-2021-00269">14</xref>&#x0005d; reported a low-grade MFS in the unilateral vocal fold, which was completely excised by laser cordectomy, with a clear surgical margin. Ocak, et al. &#x0005b;<xref ref-type="bibr" rid="b15-kjorl-hns-2021-00269">15</xref>&#x0005d; reported an intermediate-grade MFS on the arytenoid mucosa, with a positive surgical margin achieved after surgery. Our case is the first report of a high-grade MFS with an epithelioid variant in the larynx. In fact, the previously reported laryngeal MFH might be MFS. However, the concept of MFS has been affirmed since 2002, and the cases of MFS in the larynx are extremely rare since then.</p>
<p>Owing to the unique anatomical features of the larynx, wide resection of the tumor with a clear resection margin may be difficult to perform due to the critical negative effect on function, including speech and swallowing. In such cases, free flap reconstruction may be essential. Considering the generally favorable survival outcome for these tumors in relation to the negative impact of wide resection on function, the extent of initial surgery for laryngeal MFS is an issue of controversy. However, owing to the high rate of local recurrence of MFS, wide excision with a clear surgical margin may still be the treatment of choice. In our case, 1) the tumor was aggressively growing and involved the paraglottic space, and 2) the patient had old age, poor pulmonary condition, frequent aspiration tendency, and multiple co-morbidities. Roland, et al. &#x0005b;<xref ref-type="bibr" rid="b4-kjorl-hns-2021-00269">4</xref>&#x0005d; recommends wide surgical resection with a 2 cm soft tissue margin from the area of enhanced signal on T2-weighted MRI, and NCCN guideline also recommends special consideration of resection margin in the infiltrative histologies such as MFS, dermatofibrosarcoma protuberans, and angiosarcoma; therefore, total laryngectomy was inevitable to obtain a clear surgical margin. Final pathologic reports with high-grade and epithelioid variant MFS revealed total laryngectomy might be better option than laryngeal-preserving surgery. Unfortunately, we could not evaluate therapeutic outcome due to too much short follow period, long-term observation is required. Most of laryngeal malignancies originates from epithelium. Laryngeal sarcomas are relatively rare and MFS in the larynx is extremely rare. It is difficult to evaluate the treatment outcome of MFS in the larynx because there have been few studies. Still, much wider excision of tumor in MFS may be recommended than in carcinoma for better local control. Further study is required to elucidate a proper treatment.</p>
</sec>
</body>
<back>
<ack><p>None.</p></ack>
<fn-group>
<fn fn-type="participating-researchers"><p><bold>Author Contribution</bold></p>
<p>Conceptualization: all authors. Data curation: Seulki Song. Formal analysis: Jin Pyeong Kim. Funding acquisition: Seulki Song. Methodology: Seulki Song. Resources: Dae Hyun Song. Software: Seulki Song. Supervision: Jin Pyeong Kim. Validation: Seulki Song. Visualization: Seulki Song, Dae Hyun Song. Writing&#x02014;original draft: Seulki Song, Dae Hyun Song. Writing&#x02014;review &amp; editing: all authors.</p></fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-kjorl-hns-2021-00269">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Farhood</surname><given-names>AI</given-names></name>
<name><surname>Hajdu</surname><given-names>SI</given-names></name>
<name><surname>Shiu</surname><given-names>MH</given-names></name>
<name><surname>Strong</surname><given-names>EW</given-names></name>
</person-group>
<article-title>Soft tissue sarcomas of the head and neck in adults</article-title>
<source>Am J Surg</source>
<year>1990</year>
<volume>160</volume>
<issue>4</issue>
<fpage>365</fpage>
<lpage>9</lpage>
</element-citation></ref>
<ref id="b2-kjorl-hns-2021-00269">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Potter</surname><given-names>BO</given-names></name>
<name><surname>Sturgis</surname><given-names>EM</given-names></name>
</person-group>
<article-title>Sarcomas of the head and neck</article-title>
<source>Surg Oncol Clin N Am</source>
<year>2003</year>
<volume>12</volume>
<issue>2</issue>
<fpage>379</fpage>
<lpage>417</lpage>
</element-citation></ref>
<ref id="b3-kjorl-hns-2021-00269">
<label>3</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>C</given-names></name>
<name><surname>Bridge</surname><given-names>JA</given-names></name>
<name><surname>Hogendoorn</surname><given-names>PCW</given-names></name>
<name><surname>Mertens</surname><given-names>F</given-names></name>
</person-group>
<source>WHO classification of tumours of soft tissue and bone</source>
<edition>4th ed</edition>
<publisher-loc>Lyon</publisher-loc>
<publisher-name>IARC Press</publisher-name>
<year>2013</year>
</element-citation></ref>
<ref id="b4-kjorl-hns-2021-00269">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roland</surname><given-names>CL</given-names></name>
<name><surname>Wang</surname><given-names>WL</given-names></name>
<name><surname>Lazar</surname><given-names>AJ</given-names></name>
<name><surname>Torres</surname><given-names>KE</given-names></name>
</person-group>
<article-title>Myxofibrosarcoma</article-title>
<source>Surg Oncol Clin N Am</source>
<year>2016</year>
<volume>25</volume>
<issue>4</issue>
<fpage>775</fpage>
<lpage>88</lpage>
</element-citation></ref>
<ref id="b5-kjorl-hns-2021-00269">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>SW</given-names></name>
<name><surname>Enzinger</surname><given-names>FM</given-names></name>
</person-group>
<article-title>Myxoid variant of malignant fibrous histiocytoma</article-title>
<source>Cancer</source>
<year>1977</year>
<volume>39</volume>
<issue>4</issue>
<fpage>1672</fpage>
<lpage>85</lpage>
</element-citation></ref>
<ref id="b6-kjorl-hns-2021-00269">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Merck</surname><given-names>C</given-names></name>
<name><surname>Angervall</surname><given-names>L</given-names></name>
<name><surname>Kindblom</surname><given-names>LG</given-names></name>
<name><surname>Od&#x000e9;n</surname><given-names>A</given-names></name>
</person-group>
<article-title>Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis</article-title>
<source>Acta Pathol Microbiol Immunol Scand Suppl</source>
<year>1983</year>
<volume>282</volume>
<fpage>1</fpage>
<lpage>40</lpage>
</element-citation></ref>
<ref id="b7-kjorl-hns-2021-00269">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mentzel</surname><given-names>T</given-names></name>
<name><surname>Calonje</surname><given-names>E</given-names></name>
<name><surname>Wadden</surname><given-names>C</given-names></name>
<name><surname>Camplejohn</surname><given-names>RS</given-names></name>
<name><surname>Beham</surname><given-names>A</given-names></name>
<name><surname>Smith</surname><given-names>MA</given-names></name>
<etal/>
</person-group>
<article-title>Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant</article-title>
<source>Am J Surg Pathol</source>
<year>1996</year>
<volume>20</volume>
<issue>4</issue>
<fpage>391</fpage>
<lpage>405</lpage>
</element-citation></ref>
<ref id="b8-kjorl-hns-2021-00269">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sanfilippo</surname><given-names>R</given-names></name>
<name><surname>Miceli</surname><given-names>R</given-names></name>
<name><surname>Grosso</surname><given-names>F</given-names></name>
<name><surname>Fiore</surname><given-names>M</given-names></name>
<name><surname>Puma</surname><given-names>E</given-names></name>
<name><surname>Pennacchioli</surname><given-names>E</given-names></name>
<etal/>
</person-group>
<article-title>Myxofibrosarcoma: Prognostic factors and survival in a series of patients treated at a single institution</article-title>
<source>Ann Surg Oncol</source>
<year>2011</year>
<volume>18</volume>
<issue>3</issue>
<fpage>720</fpage>
<lpage>5</lpage>
</element-citation></ref>
<ref id="b9-kjorl-hns-2021-00269">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Scoccianti</surname><given-names>G</given-names></name>
<name><surname>Ranucci</surname><given-names>V</given-names></name>
<name><surname>Frenos</surname><given-names>F</given-names></name>
<name><surname>Greto</surname><given-names>D</given-names></name>
<name><surname>Beltrami</surname><given-names>G</given-names></name>
<name><surname>Capanna</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant</article-title>
<source>J Surg Oncol</source>
<year>2016</year>
<volume>114</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>5</lpage>
</element-citation></ref>
<ref id="b10-kjorl-hns-2021-00269">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Odei</surname><given-names>B</given-names></name>
<name><surname>Rwigema</surname><given-names>JC</given-names></name>
<name><surname>Eilber</surname><given-names>FR</given-names></name>
<name><surname>Eilber</surname><given-names>FC</given-names></name>
<name><surname>Selch</surname><given-names>M</given-names></name>
<name><surname>Singh</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Predictors of local recurrence in patients with myxofibrosarcoma</article-title>
<source>Am J Clin Oncol</source>
<year>2018</year>
<volume>41</volume>
<issue>9</issue>
<fpage>827</fpage>
<lpage>31</lpage>
</element-citation></ref>
<ref id="b11-kjorl-hns-2021-00269">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Neuville</surname><given-names>A</given-names></name>
<name><surname>Chibon</surname><given-names>F</given-names></name>
<name><surname>Coindre</surname><given-names>JM</given-names></name>
</person-group>
<article-title>Grading of soft tissue sarcomas: From histological to molecular assessment</article-title>
<source>Pathology</source>
<year>2014</year>
<volume>46</volume>
<issue>2</issue>
<fpage>113</fpage>
<lpage>20</lpage>
</element-citation></ref>
<ref id="b12-kjorl-hns-2021-00269">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>WO</given-names></name>
<name><surname>Cohen</surname><given-names>J</given-names></name>
<name><surname>Enzinger</surname><given-names>F</given-names></name>
<name><surname>Hajdu</surname><given-names>SI</given-names></name>
<name><surname>Heise</surname><given-names>H</given-names></name>
<name><surname>Martin</surname><given-names>RG</given-names></name>
<etal/>
</person-group>
<article-title>A clinical and pathological staging system for soft tissue sarcomas</article-title>
<source>Cancer</source>
<year>1977</year>
<volume>40</volume>
<issue>4</issue>
<fpage>1562</fpage>
<lpage>70</lpage>
</element-citation></ref>
<ref id="b13-kjorl-hns-2021-00269">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nascimento</surname><given-names>AF</given-names></name>
<name><surname>Bertoni</surname><given-names>F</given-names></name>
<name><surname>Fletcher</surname><given-names>CD</given-names></name>
</person-group>
<article-title>Epithelioid variant of myxofibrosarcoma: Expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases</article-title>
<source>Am J Surg Pathol</source>
<year>2007</year>
<volume>31</volume>
<issue>1</issue>
<fpage>99</fpage>
<lpage>105</lpage>
</element-citation></ref>
<ref id="b14-kjorl-hns-2021-00269">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gugatschka</surname><given-names>M</given-names></name>
<name><surname>Beham</surname><given-names>A</given-names></name>
<name><surname>Stammberger</surname><given-names>H</given-names></name>
<name><surname>Schmid</surname><given-names>C</given-names></name>
<name><surname>Friedrich</surname><given-names>G</given-names></name>
</person-group>
<article-title>First case of a myxofibrosarcoma of the vocal folds: Case report and review of the literature</article-title>
<source>J Voice</source>
<year>2010</year>
<volume>24</volume>
<issue>3</issue>
<fpage>374</fpage>
<lpage>6</lpage>
</element-citation></ref>
<ref id="b15-kjorl-hns-2021-00269">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ocak</surname><given-names>GA</given-names></name>
<name><surname>Ozbudak</surname><given-names>IH</given-names></name>
<name><surname>Toru</surname><given-names>HS</given-names></name>
<name><surname>Derin</surname><given-names>AT</given-names></name>
</person-group>
<article-title>Second case report of myxofibrosarcoma of larynx</article-title>
<source>Otolaryngology</source>
<year>2015</year>
<volume>5</volume>
<issue>2</issue>
<fpage>186</fpage>
</element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-kjorl-hns-2021-00269" position="float">
<label>Fig. 1.</label><caption><p>Preoperative evaluation. A: Laryngoscopic finding, showing a protruding mass in the left false vocal fold. B and C: Preoperative CT image (B) and MR image (C) showing a heterogeneously enhanced mass in the left false vocal fold and aryepiglottic fold, extending to the paraglottic fat.</p></caption>
<graphic xlink:href="kjorl-hns-2021-00269f1.tif"/></fig>
<fig id="f2-kjorl-hns-2021-00269" position="float">
<label>Fig. 2.</label><caption><p>Postoperative histopathologic and immunohistochemical findings of myxofibrosarcoma. A: The tumor consisted of spindle cells with a myxoid background; elongated, curvilinear, and thin-walled blood vessels are observed among spindle tumor cells (H&amp;E stain, &#x000d7;40). B: Spindle cells showing enlarged hyperchromatic nuclei with eosinophilic cytoplasm (H&amp;E stain, &#x000d7;100). C: Spindle tumor cells with no reaction to cytokeratin antibody (pan cytokeratin, &#x000d7;100). D: Tumor cells with positivity to vimentin antibody (vimentin, &#x000d7;100). E: CD31 immunohistochemical stain highlighting distinctive curvilinear blood vessels (CD31, &#x000d7;100). H&amp;E, hematoxylin and eosin.</p></caption>
<graphic xlink:href="kjorl-hns-2021-00269f2.tif"/></fig>
<fig id="f3-kjorl-hns-2021-00269" position="float">
<label>Fig. 3.</label><caption><p>Postoperative histopathologic and immunohistochemical findings of epithelioid variance. A: Typical histologic background of myxofibrosarcoma (arrowheads) with a partial epithelioid variant (arrows) (H&amp;E stain, &#x000d7;40). B: Higher power imaging of the region of the epithelioid variant (H&amp;E stain, &#x000d7;200). C: The epithelioid variant portion showing positivity to vimentin antibody (vimentin, &#x000d7;200). H&amp;E, hematoxylin and eosin.</p></caption>
<graphic xlink:href="kjorl-hns-2021-00269f3.tif"/></fig>
</sec>
</back></article>